Eleusis acquires a ketamine therapy provider and announces a new R&D program.
Eleusis acquires a ketamine therapy provider and announces a new R&D program.
MindMed's recent financing has closed after being upsized all the way to CAD$34.5 million.
Psychedelic stocks are hitting new highs -- and doing so on record trading volumes. Feeding frenzies.
The company is set to open a therapeutic health and training center in Kelowna, British Columbia in May of 2021
Leading psychedelic stocks have gone ballistic in recent weeks. But where will investors find the NEXT multi-bagger opportunity?
Entheon has secured a supply of DMT for delivery to its drug research center (CHDR) in the Netherlands.
Warning: This is probably not for you.
Champignon Brands names an interim CFO after Stephen Brohman resigns.
Mydecine completes its first commercial harvest of 20 kilograms of psilocybin mushrooms.
Mind Cure Health will be focusing its psychedelic drug R&D on psilocybin, ketamine and ibogaine. The Company will be pursuing both pain-based and mental health applications for psychedelics.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now